U.S. and China AI Drug Race Is Breaking Regulatory Control; FDA Pressure and Data Failures Are Escalating Fast

At BioSpace’s NextGen 2026 discussion, leading biotech executives from the United States and China highlighted a growing strategic divide in pharmaceutical innovation. The conversation revealed how artificial intelligence is now accelerating drug discovery and clinical decision-making, while simultaneously exposing weaknesses